Vizgen debuts accelerator lab in the U.S.

By The Science Advisory Board staff writers

Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.

The pharma accelerator lab was launched to meet the high demand from pharmaceutical companies who continue to turn to single-cell and spatial transcriptomics technology to speed up drug development pipelines.

Additionally, Vizgen began an early release program so scientific investigators could gain access to its multiplexed error-robust fluorescence in situ hybridization (MERFISH) platform ahead of its commercial launch.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?